(18.206.238.77) 您好!臺灣時間:2021/05/17 19:06
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

: 
twitterline
研究生:劉勇麟
研究生(外文):Liu Yung-Lin
論文名稱:Epirubicin治療犬傳染性花柳性腫瘤的療效及副作用
論文名稱(外文):Therapeutic and Side Effects of Epirubicin on Transmissible Venereal Tumor in Dogs
指導教授:張清棟張清棟引用關係
指導教授(外文):Chang Ching-Dong
學位類別:碩士
校院名稱:國立屏東科技大學
系所名稱:獸醫學系
學門:獸醫學門
學類:獸醫學類
論文種類:學術論文
論文出版年:2005
畢業學年度:93
語文別:中文
論文頁數:91
中文關鍵詞:犬 犬傳染性花柳性腫瘤 Epirubicin犬傳染性花柳性白血球電解質生化學消化道
外文關鍵詞:CanineTransmissible venereal tumorEpirubicin
相關次數:
  • 被引用被引用:0
  • 點閱點閱:301
  • 評分評分:
  • 下載下載:22
  • 收藏至我的研究室書目清單書目收藏:0
為探討抗腫瘤藥Epirubicin治療犬傳染性花柳性腫瘤 ( Canine Transmissible Venereal Tumor;CTVT ) 的療效及副作用,將實驗犬分為3組,每組6頭實驗犬,A組為6隻健康犬隻,靜脈點滴投予 Epirubicin 30 mg/m2,間隔21天,靜脈點滴投藥2次。B組為6隻健康犬隻,給予生理食鹽水為對照組,間隔21天,靜脈點滴投藥2次。C組為臨床罹患犬傳染性花柳性腫瘤犬隻;給予Epirubicin 30 mg/m2治療,間隔21天,靜脈點滴投藥2次。
結果給予抗腫瘤藥Epirubicin的兩組於試驗期間,其血清生化學檢查、血清電解質檢驗及心電圖檢查和對照組無顯著差異。但是於每次給藥後7天和給予生理食鹽水對照組比較,可發現白血球減少及血小板減少等變化。在6隻罹患犬傳染性花柳性腫瘤犬隻於Epirubicin治療期間,細胞學檢查可發現腫瘤細胞變性,細胞核變小皺縮、破裂,腫瘤細胞數逐漸的減少、淋巴球明顯逐漸增加。隨著腫瘤逐漸衰退,組織病理學檢查可發現腫瘤細胞數逐漸的減少,腫瘤細胞核變得不規則、畸形、核仁消失,淋巴球浸潤,增加纖維結締組織和血管增生等變化。
本研究結果Epirubicin可單獨使用治療CTVT患犬,以30 mg/m2靜脈點滴給藥,間隔21天,給藥2次,可使CTVT患犬7週後腫瘤完全消退。而Epirubicin會產生嘔吐、下痢的消化道症狀副作用及輕微至中等度的白血球減少症和血小板減少症等骨髓抑制副作用。消化道症狀及骨髓抑制大多可以自癒的。只要在給藥期間小心照顧減少感染,每週行完整血液學檢查監測,則Epirubicin即可安全使用於治療犬傳染性花柳性腫瘤。
In order to investigate the efficacy and side effect of Epirubicin on canine transmissible venereal tumor ( CTVT ), 18 dogs were divided into 3 groups. Group A, 6 healthy dogs were intravenously treated by Epirubicin 30 mg/m2 twice with an interval of 21 days. Group B, negative control, 6 healthy dogs were intravenously treated by normal saline twice with an interval of 21 days. Group C, 6 dogs with CTVT were intravenously treated by Epirubicin 30 mg/m2 twice with an interval of 21 days.
The results shown that no significant differences of serum chemistry, serum electrolytes and electrocardiogram were found among groups. However, leukopenia and thrombocytopenia were noticed 7 days after treatment of Epirubicin 30 mg/m2 in Group A and C. Cytologic examination of 6 dogs in Group C revealed that degeneration, pyknosis, karyorrhexis, decreased cell numbers of CTVT were observed and lymphocytes were gradually infiltrated in CTVT. Cell numbers of CTVT were decreased with degeneration and necrosis by histopathological examination. Nuclear pleomorphism, bizarre nuclei, loss of nucleoli, lymphocytic infiltration, increased fibrous connective tissues and blood vessels were observed in CTVT.
The result of this study shown that Epirubicin 30 mg/m2 can be intravenously given twice with an interval of 21 days to treat CTVT. After 7 weeks of treatment, CTVT were completely resolved. The side effects of gastrointestinal tracts of vomition and diarrhea and bone marrow depression of mild to moderate leukopenia and thrombocytopenia could be recovered with care to avoid infection. In conclusion, Epirubicin can be used to treat CTVT safely with weekly monitoring by blood examination..
Keywords:Canine, Transmissible venereal tumor, Epirubicin.
目 錄
中文摘要…………………………………………………………………… Ⅰ
Abstract..…………………………………………………………………… Ⅲ
誌謝………………………………………………………………………… Ⅴ
目錄………………………………………………………………………… Ⅵ
圖表目錄…………………………………………………………………… Ⅸ
第1章 前言………………………………………………………………. 1
第2章 文獻回顧…………………………………………………………. 3
2. 1 犬傳染性花柳性腫瘤.....…………………………………………… 3
2. 1. 1 CTVT發生、傳播和轉移……………………………………. 3
2. 1. 2 CTVT臨床症狀………………………………………………. 4
2. 1. 3 CTVT細胞學及組織病理學特徵……………………………. 5
2. 1. 3. 1 CTVT細胞學…………………………………………… 5
2. 1. 3. 2 CTVT組織病理學……………………………………… 5
2. 1. 4 CTVT細胞特性……………………………………………. 5
2. 1. 4. 1 CTVT來源……………………………………………... 5
2. 1. 4. 2 CTVT核型分析………………………………………... 6
2. 1. 5 CTVT組織培養及人工接種…………………………………. 6
2. 1. 5. 1 CTVT細胞培養………………………………………… 6
2. 1. 5. 2 CTVT人工接種………………………………………… 7
2. 1. 6 CTVT的免疫反應……………………………………………. 8
2. 1. 7 CTVT的治療…………………………………………………. 9
2. 2 Epirubicin…………………………………………………………… 10
2. 2. 1 化學治療……………………………………………………… 10
2. 2. 2 Epirubicin的發展史………………………………………….. 10
2. 2. 3 Epirubicin的理化特性……………………………………….. 11
2. 2. 4 Epirubicin藥物動力學……………………………………….. 11
2. 2. 5 Epirubicin作用機制………………………………………….. 11
2. 2. 6 Epirubicin於犬之臨床應用………………………………….. 12
2. 2. 7 Epirubicin投藥方式、劑量及療程………………………….. 12
2. 2. 8 Epirubicin的毒性及副作用………………………………….. 13
2. 2. 9 避免Epirubicin毒性對策……………………………………. 14
第3章 材料與方法………………………………………………………. 15
3. 1 實驗分組及給藥……………………………………………………. 15
3. 2 實驗材料及檢驗儀器………………………………………………. 15
3. 3 實驗方法……………………………………………………………. 18
3. 3. 1 血液學檢查…………………………………………………… 18
3. 3. 2 血液生化學檢查……………………………………………… 18
3. 3. 3 電解質檢驗…………………………………………………… 19
3. 3. 4 心電圖檢查…………………………………………………… 19
3. 3. 5 CTVT細胞學檢查…………………………………………… 19
3. 3. 6 CTVT組織病理學檢查………………………………………. 19
3. 3. 7 CTVT免疫組織化學染色法檢查……………………………. 20
3. 3. 8 CTVT電子顯微鏡檢查………………………………………. 20
3. 4 數據的統計分析................................................................................. 22
第4章 結果………………………………………………………………. 23
4. 1. 臨床症狀及外觀……………………………………………………. 23
4. 2 CTVT細胞學檢查結果…………………………………………….. 29
4. 3 CTVT組織病理學檢查結果……………………………………….. 33
4. 4 CTVT免疫組織化學染色法檢查結果…………………………….. 33
4. 5 CTVT電子顯微鏡檢查結果……………………………………….. 33
4. 6 血液學檢查結果……………………………………………………. 42
4. 6. 1 紅血球數結果………………………………………………… 42
4. 6. 2 白血球數結果............................................................................ 48
4. 6. 3 血小板數結果............................................................................ 50
4. 7 血液生化學檢查結果………………………………………………. 52
4. 8 心電圖檢查結果................................................................................. 57
4. 8. 1 心搏速率結果………………………………………………… 57
4. 8. 2 心電圖檢查P-wave width結果……………………………… 59
4. 8. 3 心電圖P-wave height結果…………………………………… 61
4. 8. 4 心電圖P-R interval 結果…………………………………….. 63

4. 8. 5 心電圖QRS complexes width結果………………………… 65
4. 8. 6 心電圖Q-T interval結果…………………………………….. 67
4. 9 電解質檢驗結果……………………………………………………. 69
第5章 討論………………………………………………………………. 72
參考文獻…………………………………………………………………… 79
附錄………………………………………………………………………… 89
作者簡介…………………………………………………………………… 91


圖表目錄
Fig. 1 Experimental protocol and flow chart…………………........ 17
Fig. 2 Immunohistochemistry protocol……………………………. 21
Fig. 3 Gross pathologic changes of dog C-1 with CTVT…………. 25
Fig. 4 Gross pathologic changes of dog C-2 with CTVT…………. 26
Fig. 5 Gross pathologic changes of dog C-3 with CTVT…………. 27
Fig. 6 Gross pathologic changes of dog C-5 with CTVT..….…….. 28
Fig. 7 Changes of body weight in dogs among groups that treated with epirubincin or normal saline…………………………... 30
Fig. 8 Cytologic examination of dog C-5 with CTVT…………….. 31
Fig. 9 Histopathologic changes of dog C-5 with CTVT…….…….. 34
Fig. 10 Histopathologic changes of dog C-5 with CTVT after chemotherapy with epirubicin……………………...………. 35
Fig. 11 Marked proliferation of fibrous connective tissues in the CTVT of dog C-2 after chemotherapy with epirubicin…….. 36
Fig. 12 Result of immunohistochemistry stain in the CTVT of dog C-3 using vimentin antibody and chromogen of DAB……………………………………………………....... 38
Fig. 13 Result of immunohistochemistry stain in the CTVT of dog C-3 using CD20 antibody and chromogen of DAB............... 39
Fig. 14 Result of immunohistochemistry stain in the CTVT of dog C-3 using CD45RO antibody and chromogen of DAB…………………………………………………...…… 40
Fig. 15 Transmission electron micrograph of the CTVT in dog C-2……………………….………………………………… 41
Fig. 16 Results of heart rate of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline……………………………………………………….. 58
Fig. 17 Results of P-wave width of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline…. 60
Fig. 18 Results of P-wave height of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline..... 62
Fig. 19 Results of P-R interval of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline……………………………………………………….. 64
Fig. 20 Results of QRS complexes of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline……………………………………………………….. 66
Fig. 21 Results of Q-T interval of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline……………………………………………………….. 68
Table. 1 Signalment of dogs used in studies on therapeutic and side effects of epirubicin on transmissible venereal tumor in dogs………………………………………………………… 16
Table. 2 Signalment and site of CTVT in dogs in Group C and results of CTVT before and after treatment with epirubicin………………………………………………....... 24
Table. 3 Results of cytologic examination of dogs with CTVT after treatment with epirubicin…………...………………………. 32
Table. 4 Results of pathologic changes of dogs with CTVT after treatment with epirubicin………………………………....... 37
Table. 5 Results of immunohistochemistry stain of CTVT in dog.................................................................................……. 41
Table. 6 Results of red blood cell ( RBC ) of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/ m2 or normal saline……………………………………………………….. 43
Table. 7 Results of packed cell volume ( PCV ) of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/ m2 or normal saline…………..……………………………............ 43
Table. 8 Results of hemoglobin ( Hb ) of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline…. 45
Table. 9 Results of mean corpuscular hemoglobin concentration ( MCHC ) of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline……………............... 45
Table. 10 Results of mean corpuscular hemoglobin ( MCH ) of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline……….......................................... 47
Table. 11 Results of mean corpuscular volume ( MCV ) of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline…………………………………………….. 47
Table. 12 Results of white blood cell ( WBC ) of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline……………………………………………….. 49
Table. 13 Results of platelet ( PLT ) of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline………………………………………………………... 51
Table. 14 Results of serum biochemistry of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline……………………………………………………….. 52
Table. 15 Results of electrolytes of healthy dogs and dogs with CTVT treated with epirubicin 30 mg/m2 or normal saline.………………………………………………………. 71
Reference Fig.1 Molecular structure of epirubicin………………….. 89
Reference Fig.2 Normal canine P-QRS-T complex in lead Ⅱ……… 90
參考文獻
李崇道。獸醫病理學。黎明文化事業公司,台北,324-325,1986。
沈永紹。獸醫實驗診斷學提要。華香園出版社,台北,43-102,1993。
陳長安。抗癌瘤藥物。常用藥物治療手冊,台北,531-534,2001。
黃冠華、蔡宗欣、林信男、楊文宏、唐一清、張建成、鄭鴻琳、林永明。卡介苗、Epirubicin及Thiotepa預防表淺性膀胱癌術後復發之比較。台灣醫學 1:389-393,1997。
洪紹文。傳染性花柳性腫瘤犬隻血液中淋巴球的變化。碩士論文。國立台灣大學獸醫學研究所。1-119,2002。
范佐勳。抗腫瘍抗生素。引自:最新藥品手冊,范佐勳主編。高華出版社,台北,871-874,2005。
楊淑如。傳染性花柳性腫瘤特性。碩士論文,國立中興大學獸醫學研究所。1-108,1996。
陸昱彬、陳智芳、張明志。Anthracycline類藥物引起之心毒性。中華癌醫會誌 17:1-9,2001。
張仕杰、楊志寰。犬皮膚型圓形細胞瘤之細胞學與組織學特徵。中華獸醫誌 25:139-152,1999。
張仕杰、陳三多。犬原發性生殖器外之傳染性花柳性腫瘤以Vincristine治療前後之細胞學變化。台灣畜牧獸醫學會會報 65:283-295, 1995。
張仕杰、楊志寰。犬傳染性花柳性腫瘤細胞之觀察。台灣畜牧獸醫學會會報 66:307-314,1996。


蘇純閨。化學療法。引自:藥理學,蘇純閨主編。合記圖書出版社。台北,641-652,1998。
Abrahamova J, Wagnerova M, Kubala E, Malec V, Simova E, Sirakova I, Pavlikova E, Machova D, Kocak I, Pavlikova I, Tuma P, Prausova J, Kroslakova D,Van Praagh I. Vinorelbine Epirubicin and Methotrexate ( VEM ) as primary treatment in locally advanced breast cancer. The Oncologist 6: 347-352, 2001.
Adams EW, Sapp WJ, Carter LP. Cytogenetic observation on the canine venereal tumor in long-term culture. Cornell Vet 71: 336-346, 1981.
Amber EI, Henderson RA. Canine transmissible venereal tumor: Evaluation of surgical excision of primary and metastatic lesion in Zaria-Nigeria. J Am Anim Hosp Assoc 18: 350-352, 1982.
Amber EI, Isitor GN, Adeyanju JB. Viral-like particles associated with naturally occurring transmissible venereal tumor in two: preliminary report. Am J Vet Res 46: 2613-2615, 1985.
Baker R, Lumsden JH. The skin. In: Color atlas of cytology of the dog and cat. Mosby Inc, USA, 45-86, 2000.
Batamuzi EK, Kessy BM. Role of exfoliative cytology in the diagnosis of canine transmissible venereal tumour. J Small Anim Pract 34: 399-401, 1993.
Batamuzi EK, Bittegeko SBP. Anal and perianal transmissible venereal tumour in a bitch. Vet Rec 129: 556, 1991.
Barger AM, Griden CB. Hematologic abnormalitics associtated with cancer therapy. In: Feldman BF, ed. Schalm’s Veterinary Hematology 5th ed. Lippincott Willians & Wikins, Philadelphia, 676-681, 2000.

Barton CL. Chemotherapy. In: Boothe DM. Small animal clinical pharmacology and therapeutics. WB Saunder Co, Philadelphia, 330-341, 2001.
Beschorner WE, Hess AD, Epstein RB. Isolation and characterization of canine venereal tumor-associated inhibitory. Cancer Res 39: 3920-3927, 1979.
Bright RM, Gorman NT, Probst CW, Goring RL. Transmissible venereal tumor of the soft plate in a dog. J Am Vet Med Assoc 183: 893-895, 1983.
Bertazzoli C, Rovero C. Experimental systemic toxicology of 4´-epidoxorubicin a new less cardiotoxic anthracycline antitumor agent. Toxicology and applied pharmacology 79: 412-22, 1985.
Boscos M. Cutaneous involvement of TVT in dog: A report of two cases. Canine Pract 24: 6-11, 1999.
Brody NO, Calvert CA, MacEwen EG. Neoplasms of canine uterus vagina and vulva: clinicopathologic survey of 90 cases. J Am Vet Med Assoc 151: 1294-1307, 1967.
Brown NO, Calvert C, MacEwen EG. Chemotherapeutic management of transmissible venereal tumors in 30 dogs. JAVMA 176: 983-986, 1980.
Brown NO, MacEwen EG. Transmissible venereal tumor in the dog. Calif Vet 3: 6-10, 1981.
Calvert CA, Leifer CE, MacEwen EG. Vincristine for treatment of transmissible venereal tumor in the dog. J AM Vet Med 181: 163-164, 1982.
Cave TA, Hine R, Howie F, Thompson H, Argyle DJ. Uterine carcinoma in a 10 month-old golden retriever. J Small Anim Pract 43: 133-135, 2002.
Cockrill JM, Beasley JN. Ultrastrutural characteristics of canine transmissible venereal tumor at various stages of growth and regression. Am J Vet Res 36: 677-681, 1975.
Cohen D, Steel GG. Thymidine labelling studies in a transmissible venereal tumour of the dog. Br J Cancer 26: 413-419, 1972.
Cohen D. The mechanism of transmission of the transmissible venereal tumour of the dog. Transplantation 17: 8-11, 1974.
Cohen D, Shalev A, Krup M. Lack of beta 2-microglobulin on the surface of canine transmissible venereal tumor. J Natl Cancer Inst 72: 395-401, 1984.
Couto CG. Complications of cancer chemotherapy. In: Nelson RW, Couto CG, eds. Small animal internal medicine. 3rd ed. Mosby Inc, Philadelphia, 1108-1116, 2003.
Das U, Das AK. Review of canine transmissible venereal sarcoma. Vet Res Com. 24: 545-556, 2000.
Dass LL, Sahay PN, Khan AA, Jha GJ. Malignant transmissible venereal tumor. Canine Pract 13: 15-18, 1986。
Davis LE. Topics in drug therapy Doxorubicin therapy in the dog. JAVAM 182: 70-72, 1983.
Dobson JM, Gorman NT. Cytotoxic agents. In: Cancer chemotherapy in small animal practice. Black well scientific publication , London, 29-66, 1993.
Dobson JM. Principles of cancer therapy. In: Dunn J, ed. Textbook of small animal medicine. WB Saunder Co, London, 985-1028, 1999.
Einstein R, Jones R, Knifton A, Starmer G. Chemotherapy and immunotherapy of neoplasia. In: Veterinary Therapeutic, PTE Ltd, 535-545, 1994.
Eissa S, Shoman S. Tumor classification markers-tissue antigen used as markers for diagnosis. In: Tumor markers. Chapman & Hall, Philadelphia, 56, 1998.
Epstein RB, Bennett BT. Histocompatibility typing and course of canine venereal tumors transplanted into unmodified random dogs. Cancer Res 34: 788-793, 1974.
Frimberger AE. Anticancer drugs: new drugs or applications for veterinary medicine. In: Bonagura JD. Kirk’s Current Veterinary TherapyⅩⅢ Small animal practice WB Saunders Co, USA, 474, 2000.
Ferreira AJ, Jaggy A, Varejao AP, Ferreira ML, Correia JM, Mulas JM, Almeida O, Oliveira P, Prada J. Brain and ocular metastases from a transmissible venereal tumor in a dog. J Small Anim Pract 41: 165-168, 2000.
Ganzina F. 4´-epi-doxorubicin a new analogue of doxorubicin : a preliminary overview of preclinical and clinical data. Cancer Treat Rev 10: 1-20, 1983.
Ginel PJ, Molleda JM, Novales M, Martin E, Margarito JM, Lopez R. Primary transmissible venereal tumor in the nasal cavity of a dog. Vet Rec 136: 222-223, 1995.
Gonzalez CM, Griffey SM, Naydan DK, Flores E, Cepeda R, Cattaneo G, Madewell BR. Canine transmissible venereal tumor : a morphological and immunohistochemical study of 11 tumours in growth phase and during regression after chemotherapy. J Comp Pathol 122: 241-248, 2000.
Goldschmidt MH, Hendrick MJ. Tumor of the skin and soft tissues. In: Tumor in domestic animals. 4th ed. Blackwell publishing Co, 115, 2002.
Grasselli G, Vigano L, Capri G, Capri G, Locatelli A, Tarenzi E, Spreafico C, Bertuzzi A, Giani A, Materazzo C, Cresta S, Perotti A, Valagussa P, Gianni L, Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. J Clin Oncol 19: 2222-2231, 2001.
Gruel A, Kuscu B, Gulanber EG, Arun SS. Transmissible venereal tumors detected in the extragenital organs of dogs. Israel Vet Med Ass 57: 1-7, 2002.
Hahn KA, Hahn EA. Epirubicin chemotherapy. In: Kirk RW, ed. Current veterinary therapy ⅩⅠ. WB Saundes Co, Philadelphia, 392-395, 1992.
Hamlin RL. Clinical toxicology of cardiovascular drugs. Vet Clin of Nor Am Small Anim Pract 20: 469-481, 1990.
Harmelin A, Pinthus JH, Katzir N, Kapon A, Volcani Y, Amariglio EN, Rehavi G. Use of murine xenograft model for canine transmissible venereal tumor. Am J Vet Res 62: 907-11, 2001.
Hasler AH, Weber WT. Theriogenology question of the month Transmissible venereal tumor ( TVT ). J AmVet Med Assoc 216: 1557-1559, 2000。
Hohenhaus AE, Peaston AE, Maddison JE. Cancer chemotherapy. In: Maddison J, Page S, Churh D, eds. Small clinical pharmacology. WB Saunders Co, London, 293-326, 2002.
Kroger D, Grey RM, Boyd JW. An unusual presentation of canine transmissible venereal tumor. Canine Pract 16: 17-21, 1991.
Lahtinen R, Kuikka J, Nousiainen T, Uusitupa M, Lansimies E. Cardiotoxicity of epirubicin and doxorubicin: A double-blind randomized study. Eur J Haematol 46: 301-305, 1991.

Launchbury AP, Habboubit N. Epirubicin and doxorubicin: a comparison of their characteristics therapeutic activity and toxicity. Cancer Treat Rev 19: 197-228, 1993.
MacEwen GE. Transmissible venereal tumor. In:Withrow ST, MacEwen GE, eds. Small aninal clinical oncology. WB Saunders Co, USA, 533-536, 1996.
Makino S. Some epidemiologic aspects of venereal tumors of dog as revealed by chromosome and DNA studies. Ann NY Ascad Sci 108: 1106-1122, 1963.
Marchal T, Chabanne L, Kaplanski C, Rigal D, Magnol JP. Immunophenotype of the canine transmissible venereal tumor. Vet Immunol Immunopathol 57: 1-11, 1997.
Mizuno S, Fujinaga T, Tajima M, Otomo K, Koike T. Role of lymphocytes in dogs experimentally re-challenged with canine transmissible sarcoma. Jpn J Vet Sci 51: 86-95, 1989.
Moulton JE. Tumor of genital system. In:Moulton J E. Tumors in domestic animals. 2nd ed. Blackwell Publishing Co, California, 326-330, 1978.
Mozos E, Mendez A, Gomez-Villamandos JC, Martin De Las Mulas J, Perez J. Immunohistocemical characterization of canine transmissible venereal tumor. Vet Pathol 33: 257-63, 1996.
Murray M, James ZH, Martin WB. A study of the cytology and karyotype of the canine transmissible venereal tumour. Res Vet Sci 10: 565-568, 1969.
Nesbit EA, Bain PJ, Northrup NC, Latimer KS. Canine round cell tumor. Depart of pathology. 01, 20, 2004. 2002.
http//www.Vet.uga.edu/vpp/clerk/Nesbit/index.html.

Nielsen SW, Kennedy PG. Tumors of the genital system. In: Moulton JE, ed. Tumors in domestic animals. 3rd ed. Berkeley, University of California , 495-502, 1990.
Oduye OO, Ikede BO, Esuruoso GO, Akpokoje TU. Metastatic transmissible venereal tumor in the dog. J Small Anim Pract 14: 625-637, 1973.
Okamoto Y, Minami S, Matsuhashi A, Fujinaga T. Isolation of vable cells in canine transmissible sarcoma ( CTS ) using density gradient centrifugation. J Vet Med Sci 58: 1149-1151, 1996.
Otomo K, Koike T, Kudo T, Sakari T. Histological and ultrastructural findings of regressing canine transmissible venereal tumour after repeated transplantation. Jap J Vet Sci 43: 823-832, 1981.
Page RL. Chemotherapy: pharmacolog and toxicologic cosidrations. In: Kirk RN, ed. Current veterinary therapy ⅩⅡ. WB Saunder Co, Philadelphia, 402-405, 1995.
Palker TJ, Yang TJ. Identification and physicochemical characterization of a tumor-associated antigen from canine transmissible venereal sarcoma. J Natl Cancer Inst 66: 779-787, 1981.
Perez J, Bautista MJ, Carrasco L, Gomez-villamandos JC, Mozos E. Primary extragenital occurrence of transmissible venereal tumors: three case reports. Canine Pract 19: 7-10, 1994.
Perez J, Day MJ, Mozos E. Immunohistochemical study of the local inflammatory infiltrate in spontaneous canine transmissible venereal tumor at different stages of growth. Vet Immunol Immumopathol 64: 133-147, 1998.
Powers RD. Immunologic properties of canine transmissible venereal sarcoma. A M J Vet Res 29: 1637-1645, 1968.
Powers BE. The pathology of neoplasia. In: Withow SJ, MacEwen EG, eds. Small animal clinical oncology. 2nd ed. WB Saunder Co, Philadelphia, 4-15, 1996.
Prier JE. Chromosome pattern of canine transmissible sarcoma cell in culture. Nature 212: 724-726, 1966.
Rickards DA. Cryotherapy on a transmissible venereal tumor in male dog. Canine Pract 10: 37-39, 1983.
Rogers KS. Transmissible venereal tumor. Comp on Contin Edu for the Pract Vet 19: 1036-1045, 1997.
Rogers KS, Walker MA, Dillon HB. Transmissible venereal tumor: a retrospective study of 29 cases. J Am Anim Hosp Assoc 34: 463-470, 1998.
Sandusky GE, Carlton WW, Wightman KA. Diagnostic Immunohistochemistry of canine round cell tumors. Vet Pathol 24: 495-499, 1987.
Scott DW, Miller WH, Griffin CE . Neoplastic and non-neoplastic tumors. In: Muller & Kirk’s Small animal dermatology. 6th ed. WB Saunders Co, Philadelphia, 1365-1368, 2001.
Simonson ER, Kraegel SA. Practical mechanics of drug delivery. In: Bonagura JD, ed. Kirk’s current veterinary therapy ⅩⅢ. Small animal Practice. WB Saunder Co, Philadelphia, 462-465, 2000.
Singh J, Rana JS, Sood N, Pangawkar GR, Gupta PP. Clinico-pathological studies on the effect of different anti-neoplastic chemotherapy regimens on transmissible venereal tumours in dogs. Vet Res Com 20: 71-81, 1996.
Spence JA, Holt PE, Sayer PD, Pottcher D, Cooper JE. Metastasis of transmissible venereal tumor to the pituitary. J Small Anim Pract 19: 175-184, 1978.
Tilley LP. Essentials of canine and feline electrocardiography : interpretation and treatment. 3rd ed. Lea & Febiger, USA, 59-99, 1992.
Tyler RD, Cowell RL, Meinkoth JH. Cutaneous and subcutaneous lesion. In: Cowell RL, Tyler RD, Meinkoth JH, eds. Diagnostic cytology and hematology of the dog and cat. 2nd ed. Mosby Inc, USA, 33-39, 1989.
Venturini M, Lunardi G, Mastro LD,Vannozzi MO, Tolino G, Numico G, Viale M, Pastone I, Angiolini C, Bertelli G, Straneo M, Rosso R, Esposito M. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. Am Soc Clin Onco 18: 2116-2125, 2000.
Vermooten MI. Canine transmissible venereal tumour ( TVT ): A revirw. J Safr Vet Assoc 58: 147-150, 1987.
Wright PJ, Parry BW. Cytology of the canine reproductive system. Vet Clin of Nor Am Small Anim Pract 19: 851-874, 1989.
Yager JA, Wilcock BP. Round cell tumors. In: Color atlas and text of surgical pathology of the dog and cat dermatopathology and skin tumors. 2nd ed. Wolfe, London, 273-286, 1994.
Yang TJ. Metastatic transmissible venereal sarcoma in a dog. J Am Vet Assoc 190: 555-558, 1987.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top